|1.||Matsuyama, Wataru: 3 articles (01/2008 - 05/2006)|
|2.||Higashimoto, Ikkou: 3 articles (01/2008 - 05/2006)|
|3.||Osame, Mitsuhiro: 3 articles (01/2008 - 05/2006)|
|4.||Arimura, Kimiyoshi: 3 articles (01/2008 - 05/2006)|
|5.||Mitsuyama, Hideo: 2 articles (01/2008 - 01/2007)|
|6.||Koreeda, Yoshimizu: 2 articles (01/2008 - 01/2007)|
|7.||Cazzola, M: 2 articles (01/2003 - 03/2002)|
|8.||Boveri, B: 2 articles (01/2003 - 03/2002)|
|9.||Casanova, F: 2 articles (01/2003 - 03/2002)|
|10.||Santus, P: 2 articles (01/2003 - 03/2002)|
|1.||Chronic Obstructive Pulmonary Disease (COPD)
03/01/2002 - "Our data suggest that oxitropium bromide bronchodilator activity is effective in exacerbations of COPD."
12/01/1993 - "We conclude that oxitropium bromide is an effective and safe bronchodilator for even elderly patients with COPD."
01/01/1994 - "Twelve patients suffering from partially reversible chronic obstructive pulmonary disease (COPD) took past in a single blind, randomised, 4-way cross-over trial to determine the optimal dose and duration of action of the anticholinergic agent oxitropium bromide (OTB) inhaled as a nebulised solution. "
06/01/1992 - "We studied 32 patients with stable COPD, mean age 65 yrs, in a double-blind, placebo-controlled, cross-over trial of the inhaled anticholinergic drug, oxitropium bromide. "
01/01/2002 - "An initial search was carried out using the Cochrane Airways Group COPD RCT register using the search terms: (nasal ventilat* OR positive pressure OR NIPPV). "
|2.||Asthma (Bronchial Asthma)
01/01/1989 - "Oxitropium bromide (OXBR) is a new anticholinergic drug, which is expected to be useful in the treatment of nocturnal asthma. "
12/01/1996 - "The short-term and long-term effects of the anticholinergic agent oxitropium bromide (CAS 30286-75-0, OTB) were studied in nine elderly patients with bronchial asthma (8 men and 1 women, age: 69.5 +/- 5.2 years, 3 atopic and 6 (not atopic cases). "
12/01/1996 - "Effectiveness of the anticholinergic agent oxitropium bromide in elderly patients with bronchial asthma."
10/01/1986 - "Eighteen patients (aged 18 to 76 years; seven men) with documented nocturnal asthma were studied in a double-blind randomized cross-over study in which they received either oxitropium bromide (200 micrograms or 400 micrograms) or placebo in a single dose at night for two-week periods. "
10/01/1986 - "To examine this hypothesis, we have studied the effect of an anticholinergic drug, oxitropium bromide, on the early morning fall in peak expiratory flow (PEF) in patients with nocturnal asthma. "
04/01/2004 - "The mean (SD) increase in FEV(1) after oxitropium bromide administration was significantly greater in patients with active HCV (95  mL) than in HCV-negative asthmatic patients (68  mL) and asthmatic patients with inactive HCV infection (69  mL; p < 0.001). "
04/01/2004 - "Increased responses to inhaled oxitropium bromide in asthmatic patients with active hepatitis C virus infection."
02/01/1994 - "The mean PEFR showed a statistically significant fall in morning values during the early stages of infection which lessened with recovery but no effect of treatment with oxitropium bromide was observed (P > 0.05). "
04/01/2004 - "In patients with asthma, active HCV infection is associated with increased bronchodilator responses to inhaled oxitropium bromide. "
02/01/1994 - "5. Oxitropium bromide, which inhibits the cough response to UNDW, does not offer an effective therapy for cough associated with an upper respiratory tract viral infection."
04/01/1988 - "Pretreatment with 200 micrograms of a topically active anticholinergic agent, oxytropium bromide, prevented the rise in NAR caused by 12 mumol of MCH but not that caused by 40 nmol of SP in six patients suffering from rhinitis. "
07/01/1998 - "Oxitropium bromide inhalation induced an increase in FEV1 that was significantly greater in allergic rhinitis patients with high serum IgE (155+/-20 mL (mean+/-SEM), p<0.05) than in healthy subjects (64+/-21 mL) or those with allergic rhinitis but low serum IgE (82+/-21 mL, p<0.05). "
09/01/2011 - "Incubation with oxitropium bromide of untreated diaphragm muscle and diaphragm muscle injected with endotoxin did not increase the force-frequency curves dose-dependently in vitro; however, it caused both types of muscle to be fatigue resistant. "
09/01/2011 - "In addition, the changes of fatigue resistance provoked by oxitropium bromide, which also is speculated to antagonize mAChR, may be beneficial in the treatment of patients with COPD."
01/01/2008 - "Likewise, the scores for dyspnea, fatigue, emotional function, mastery, total scores and ADLs were significantly higher at 12, 24 and 52 weeks compared with the baseline values in the procaterol group (p < 0.05, p < 0.01), but did not differ at any point in the oxitropium group (p > 0.05). "
|5.||Histamine (Histamine Dihydrochloride)
|6.||Acetylcholine (Acetylcholine Chloride)
|7.||Immunoglobulin E (IgE)
|10.||Ipratropium (Ipratropium Bromide)
|1.||Metered Dose Inhalers (Metered Dose Inhaler)